Massimo Cristofanilli, MD, FACP
Massimo Cristofanilli, MD, FACP, serves as the director of breast medical oncology, the associate director of precision oncology at the Meyer Cancer Center (MCC), and the coleader of the MCC Breast Cancer Disease Management Team, as well as the ccientific director of the Englander Institute of Precision Medicine.
Articles
Case 2: Recommendations for Approaching Treatment of HR+ Breast Cancer
March 7th 2022A panel of breast cancer experts share recommendations for adjuvant chemotherapy and endocrine therapy for a patient with HR-positive breast cancer and discuss approaches to toxicity management to increase adherence to therapy.
Case 1: Clinical Implications From MonarchE in HR+ Early Breast Cancer
February 28th 2022Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, share insight on applying data presented from the monarchE study and the use of adjuvant abemaciclib in clinical practice for high-risk, HR+ early breast cancer.
Case 1: Using Adjuvant Abemaciclib for High-Risk HR+ Early Breast Cancer
February 28th 2022Joyce O’ Shaughnessy, MD; Sunil Badve, MD, FRCPath; and Massimo Cristofanilli, MD, FACP, consider the role of adjuvant abemaciclib plus endocrine therapy for the treatment of patients with high-risk, node-positive, HR+ early breast cancer.
Case 1: MonarchE Study in High-Risk, HR+ Early Breast Cancer
February 28th 2022Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’ Shaughnessy, MD, review the study design and clinical implications from the monarchE study for high-risk, HR+ early breast cancer.
Next Steps Following PALOMA3 Trial for Breast Cancer
June 23rd 2015Massimo Cristofanilli, MD, Jefferson University Physician, professor, director, Breast Care Center, Jefferson University Hospital, discusses the next steps following the PALOMA3 trial, which was a randomized, placebo-controlled phase III study examining palbociclib plus fulvestrant in pre- and post-menopausal patients with ER-positive breast cancer.
